Several researches showed that EZH2 was a drug-related resistant gene [14, 20, 21], our research also confirmed EZH2 made pancreatic cancer cells become insensitive to gemcitabine (Fig. S4a, b). Here, EZH2 is linked to familial pancreatic carcinoma.